WO2005118522A1 - Monomethylphytosphingosine- polyethylenegly col and the composition for anti-cancer containing the same - Google Patents
Monomethylphytosphingosine- polyethylenegly col and the composition for anti-cancer containing the same Download PDFInfo
- Publication number
- WO2005118522A1 WO2005118522A1 PCT/KR2005/001438 KR2005001438W WO2005118522A1 WO 2005118522 A1 WO2005118522 A1 WO 2005118522A1 KR 2005001438 W KR2005001438 W KR 2005001438W WO 2005118522 A1 WO2005118522 A1 WO 2005118522A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- cancer
- monomethylphytosphingosine
- mmps
- derivative
- Prior art date
Links
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract description 52
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000001093 anti-cancer Effects 0.000 title claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 40
- 201000011510 cancer Diseases 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 150000003408 sphingolipids Chemical class 0.000 claims abstract description 20
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 11
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims description 27
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- MAAURYNELXQQRK-NPKQBVGDSA-N (3R,4S,5R)-3-amino-2,4,5-trihydroxynonadecanal Chemical compound C(=O)C(O)[C@H](N)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MAAURYNELXQQRK-NPKQBVGDSA-N 0.000 abstract description 18
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 230000004663 cell proliferation Effects 0.000 abstract description 7
- 231100000419 toxicity Toxicity 0.000 abstract description 7
- 230000001988 toxicity Effects 0.000 abstract description 7
- 241000124008 Mammalia Species 0.000 abstract description 6
- 230000001976 improved effect Effects 0.000 abstract description 5
- 230000004614 tumor growth Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000002829 reductive effect Effects 0.000 abstract description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 20
- 229940106189 ceramide Drugs 0.000 description 20
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 20
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 20
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 11
- 229940041181 antineoplastic drug Drugs 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 150000002305 glucosylceramides Chemical class 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 108010035597 sphingosine kinase Proteins 0.000 description 5
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229940014800 succinic anhydride Drugs 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 3
- JKBAAUMLHIUPKO-AWHXWDPHSA-N 2-[(E,1R,2R)-1-amino-2-hydroxyheptadec-3-enyl]-2-hydroxypropanedial Chemical compound C(=O)C(O)([C@H](N)[C@H](O)\C=C\CCCCCCCCCCCCC)C=O JKBAAUMLHIUPKO-AWHXWDPHSA-N 0.000 description 3
- 102000004201 Ceramidases Human genes 0.000 description 3
- 108090000751 Ceramidases Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 3
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical group CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 3
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000015785 Serine C-Palmitoyltransferase Human genes 0.000 description 2
- 108010024814 Serine C-palmitoyltransferase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 125000005313 fatty acid group Chemical group 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- PAEZRCINULFAGO-OAQYLSRUSA-N (R)-homocamptothecin Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC=CC=C3N=C21 PAEZRCINULFAGO-OAQYLSRUSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000252794 Sphinx Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940101006 anhydrous sodium sulfite Drugs 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091000114 ceramide glucosyltransferase Proteins 0.000 description 1
- 125000001549 ceramide group Chemical group 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003008 fumonisin Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SMTGDXIILDYVOM-OTWHNJEPSA-N n-[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]formamide Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC=O SMTGDXIILDYVOM-OTWHNJEPSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 229950008902 safingol Drugs 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003890 succinate salts Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
Definitions
- the present invention relates to a derivative of sphingolipid having an anti-cancer activity and a composition containing the same, and more particularly to a monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative formed by combining monomethylphytosphingosine (MMPS), which is a derivative of sphingolipid, with polyethyleneglycol (PEG) or a pharmaceutically acceptable salt thereof and a composition containing the same.
- MMPS-PEG monomethylphytosphingosine-polyethyleneglycol
- Sphingolipid was firstly found by Thudichum in 1884 and named as a sphinx like substance. It was known as a substance playing a substantial role in life phenomena as well as regulating cell growth, proliferation and differentiation.
- the sphingolipid in a human body has sphingosine, phytosphingosine or sphinganine backbones and 300 or more kinds of derivatives including ceramide having fatty acids connected to the backbones.
- the sphingolipid is a main ingredient constituting a cell membrane together with phospholipid and has polar and non-polar parts.
- Ceramide having a fatty acid connected to sphingolipid is known as a substance playing an important role in causing various action mechanisms occurring in a cell. In particular, it takes part in a cell proliferation, a cell differentiation, a temporary growth arrest of the cell proliferation and an apoptosis.
- the ceramide is a substance causing an apoptosis which is an importance mechanism for a cancer treatment and thus development of an anti-cancer drug is focused on the ceramide. It is analyzed that many anti-cancer drugs, which are being currently used or developed, influence on a biosynthesis pathway of the ceramide and thus exhibit their effects.
- ceramide and ceramide derivative and analog are directly treated to the cancer cell or a substance inducing or starting a de novo synthesis of ceramide may be used as an anti-cancer drug.
- P-drug which has been actively researched as an anti-cancer drug in recent years, is a ceramide analog of aminoalcohols.
- PDMP D-threo-l-phenyl-2-decanoylamino-3-mo holino-l-propanol
- PDMP D-threo-l-phenyl-2-decanoylamino-3-mo holino-l-propanol
- PPMP D-1hreo-l-phenyl-2-palmitoylamino-3-mo ⁇ holino-l-propanol
- PPPP P4D-1hreo-l-phenyl-2-palmitoylamino-3-pyrrolidino-l-propanol
- the P-drug is expected to exhibit an anti-cancer effect for a general cancer cell and to inhibit a synthesis of GlcCer relating to tolerance to the anti-cancer drug, thereby contributing to a prevention of drug resistance.
- B13 or N-oleoylethanolamine which are ceramidase inhibitors, is also a ceramide analog and inhibits a decomposition of the ceramide to induce a death of the cancer cell.
- ceramide biosynthesis inhibitors having a structure similar to those of sphingolipid and ceramide, such as FTY-720, fumonisin and myriosin, etc.
- DMS dimethylsphingosine
- the polyethylene glycol above mentioned is a substance having a structure of HO- (CH CH O) CH CH -OH, and often used in foods or cosmetics. In addition, since it 2 2 n 2 2 retards decomposition of an active ingredient, it has been much used in prescription of drug.
- the polyethylene glycol is a substance suitable for such purposes since it is a non-toxic polymer, has a good solubility and no antigenicity in a human body and is easily removed in the body.
- polyethylene glycol Since the polyethylene glycol has a hydroxyl group at both ends thereof, monomethoxy polyethylene glycol (CH 3 O-(CH 2 CH 2 O) n CH 2 CH 2 -OH) having one end blocked is much used in PEGylation and its molecular weight is used up to 30,000 Daltons.
- a hydroxyl group at one end having no methoxy connected thereto is activated and connected using various chemicals.
- MMPS-PEG monomethylphytosphingosine- polyethyleneglycol
- the object of the present invention is to inhibit a growth of tumor xenografted to a mammal using a derivative of sphingolipid, i.e., a monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative formed by combining monomethylphytosphingosine (MMPS) with polyethyleneglycol (PEG), thereby treating or preventing a cancer or a cancer-related disease.
- Another object of the invention is to inhibit an activity of promoting a cell proliferation, thereby treating or preventing a hyper-proliferative disease such as a cancer and psoriasis.
- the object of the invention is to provide a tumor inhibiting composition, an anti-cancer composition or composition for treating or preventing a hyper-proliferative disease, which compositions have the above-mentioned efficacies.
- MMPS-PEG monomethylphy- tosphingosine-polyethyleneglycol
- R is independently hydrogen, alkyl group of C , alkenyl group of C , alkynyl group of C , acyl group or aryl group, in a case of acyl group (COR ), R is alkyl group, alkenyl group, alkynyl group or aryl group, a substituent X is a medium used to combine with sphingolipid and -NR -, -O-, -S-, or X -alk-X , R is hydrogen, alkyl group of C 1-6 , acyl group or aryl group, X 1 and X2 are independently amino group, amido group, carboxyl group, carbamate group, carbonyl group, urea or phosphoro, and alk is alkylene of C .
- the polyethyleneglycol has a molecular weight of 550 ⁇ 10,000, more preferably, 750 ⁇ 5,000 and an end replaced with methoxy.
- a representative example of the monomethylphytosphingosine-polyethyleneglycol derivatives according to the invention is one wherein R is independently hydrogen, alkyl group or acyl group, X is succinate and the polyethyleneglycol has a molecular weight of 750 ⁇ 5,000 and an end replaced with methoxy group.
- a tumor inhibiting composition containing the monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative or a pharmaceutically acceptable salt thereof as an effective ingredient.
- MMPS-PEG monomethylphytosphingosine-polyethyleneglycol
- the tumor inhibiting composition is used to treat or prevent a cancer or cancer-related disease.
- an anti-cancer composition for treating or preventing a cancer containing the monomethylphytosphingosine- polyethyleneglycol (MMPS-PEG) derivative or a pharmaceutically acceptable salt thereof as an effective ingredient.
- MMPS-PEG monomethylphytosphingosine- polyethyleneglycol
- composition for treating or preventing a hyper-proliferative disease containing the monomethylphytosphingosine- polyethyleneglycol (MMPS-PEG) derivative or a pharmaceutically acceptable salt thereof as an effective ingredient.
- MMPS-PEG monomethylphytosphingosine- polyethyleneglycol
- the hyper-proliferative disease is psoriasis.
- composition of the invention containing the monomethylphytosphingosine- polyethyleneglycol (MMPS-PEG) derivative or a pharmaceutically acceptable salt thereof can be used in a medicine.
- the salt is not specifically limited if it is pharmaceutically acceptable.
- hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid, acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methane sulfonic acid, benzene sulfonic acid, toluene sulfonic acid and naphthalene sulfonic acid, etc. can be used.
- the monomethylphytosphingosine-polyethyleneglycol derivative having the chemical formula 1 according to the invention can be prepared by reacting monomethylphytosphingosine having a following chemical formula 2 with polyethyleneglycol which is activated in advance in a solvent under presence of catalyst.
- the MMPS-PEG derivative or the pharmaceutically acceptable salt thereof according to the invention highly inhibits a growth of tumor xenografted to the mammal, thereby treating or preventing a cancer or a cancer-related disease.
- a solubility of the monomethylphytosphingosine is improved and a toxicity thereof influencing on the human body is reduced, thereby remarkably expanding the application ranges thereof. Accordingly, the composition containing the same can be efficiently used as a tumor inhibiting composition, an anti- cancer composition for treating or preventing a cancer or a cancer-related disease or a composition for treating or preventing a hyper-proliferative disease.
- FIG. 1 is a graph showing an anti-cancer efficacy of a MMPS-PEG derivative in a nude mouse.
- FIG. 2 is a graph showing a survival rate of a nude mouse having a tumor grafted thereto which is treated with the MMPS-PEG derivative.
- a detailed description of a method of manufacturing the monomethylphy- tosphingosine-polyethyleneglycol derivative having the chemical formula 1 is as follows. Firstly, polyethyleneglycol is activated. Succinic anhydride is added to the polyethyleneglycol under presence of an organic solvent, thereby converting an alcohol group into a carboxyl group. An acid part of the polyethyleneglycol having carboxyl group replaced is activated using triethylamine and p-toluenesulfonylchloride and then a small amount of monomethylphytosphingosine is added to the activated solution a small amount by a small amount, thereby completing a 24 hours reaction under warming conditions.
- the compound having the chemical formula 1 prepared as described above is extracted using an organic solvent such as chloroform or a mixed solution of chloroform and methanol and then purified with an adsorption chromatography by silica gel.
- the purified monomethylphytosphingosine-polyethyleneglycol derivative can be used in a medicine as it is or in a form of pharmaceutically acceptable salt.
- the salt is not specifically limited if it is pharmaceutically acceptable.
- hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid, acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methane sulfonic acid, benzene sulfonic acid, toluene sulfonic acid and naphthalene sulfonic acid, etc. can be used.
- the polyethyleneglycol has preferably a molecular weight of 550 ⁇ 10,000, more preferably 700 ⁇ 5,000.
- the range of the molecular weight is the most optimal range for achieving a purpose of combining the polyethyleneglycol.
- a pharmaceutical composition containing the monomethylphy- tosphingosine-polyethyleneglycol derivative or the pharmaceutically acceptable salt thereof preferably contains 0.001 ⁇ 20 wt.% of the compound in a total composition.
- concentration is less than 0.001 wt.%, it is difficult to obtain the efficacy and when the concentration is more than 20 wt.%, it can cause an abnormality of a generative function.
- the monomethylphytosphingosine-polyethyleneglycol derivative of the invention inhibits a growth of tumor grafted in a living mammal and has an increased solubility and a decreased toxicity.
- the inventors measured an in vivo anti-cancer activity using a derivative of sphingolipid, i.e., the monomethylphytosphingosine-polyethyleneglycol derivative (MMPS-PEG) having the chemical formula 1 formed by combining monomethylphytosphingosine (MMPS) with polyethyleneglycol (PEG).
- MMPS-PEG monomethylphytosphingosine-polyethyleneglycol derivative
- PEG polyethyleneglycol
- a pharmaceutical composition containing the monomethylphytosphingosine-polyethyleneglycol derivative and the pharmaceutically acceptable salt thereof may further comprise proper carrier, excipient and diluent typically used to prepare the pharmaceutical composition.
- the compound of the invention can be pharmaceutically administrated in a form of a pharmaceutically acceptable salt thereof. Further, it can be administrated solely or in conjunction with and in a proper combination with other pharmaceutically acceptable active compounds.
- the pharmaceutical composition containing the compound of the invention can be used in forms of oral formulation such as acida, granulum, tablet, capsule, suspension, emulsion, syrup and aerosol, external preparations such as ointment and cream, suppository and sterilizing injection solution according to typical methods. Further, it can be formulated in any forms suitable for pharmaceutical preparations.
- a preferable dosage of the compound according to the invention varies with ages, sexes, weights, symptoms and degrees of diseases of administration subjects, drug forms, administration routes and administration periods, it can be properly selected by a skilled person in the art. However, considering a preferable efficacy, it is preferred that the compound of the invention is administrated in an amount of 0.001 ⁇ 1000 mg/kg per a day. The administration can be performed one time or many times per a day. In addition, the dosage can be increased or decreased according to the ages, sexes, weights, degrees of diseases and administration routes, etc. Accordingly, the dosage does not limit a scope of the invention in any way.
- the compound of the invention can be administrated to a mammal such as a rat, a mouse, a domestic animal and a human through various routes, for example, non-oral and oral administrations. All types of the administration can be expected. For instance, it can be administrated with oral, rectum or vein, muscle, hypodermic, and intrauterine dura mater or intracerebroventricular injections.
- Example 1 synthesis of monomethylphytosphingosine-polyethylenegl col (MMPS-PEG) derivative
- a sufficient amount of human breast cancer cell line i.e., MDA-MB-231 (obtained from Korea Institute of Radiological and Medical Sciences, Gongneung- dong, Seoul) was cultivated and about 10 of cells were injected into nude mouses (6-week of age, about 20 g, 6 (six) per group, SLC, Japan). After few days, when a size of tumor was increased to about 3 mm, the MMPS-PEG derivative of the Example 1 was injected in the nude mouse (125 mg/kg, three times of intraperitoneal administration) and fractionation-injection conditions of test materials were set while measuring the tumor size.
- MDA-MB-231 obtained from Korea Institute of Radiological and Medical Sciences, Gongneung- dong, Seoul
- the tumor size was measured using calipers per day and a survival rate of the treatment group was evaluated.
- phosphate buffered solution PBS
- TAXOL TAXOL
- MMPS-PEG derivative 125 mg/kg, three times of intraperitoneal administration
- TAXOL 30 mg/kg, three times of intraperitoneal administration
- MMPS-PEG derivative was added to a solution of hydroxypropyl b-cyclodextrin in purified water while stirring it. Hydrochloric acid was added to be a solution and then sodium hydroxide was added to be pH 6.0. This solution was added to a dispersion solution of carrageenan PJ in propylene glycol while mixing it. The mixture was heated to 50 °C while slowly mixing, and added with ethyl alcohol and then cooled to about 35 °C. A remaining amount of purified water was added to the mixture and then the mixture was mixed to be homogeneous.
- Migliol 812, MMPS-PEG derivative and polysorbate 80 were mixed. Phosphatidyl choline was dissolved in ethanol and then added to the mixture to obtain a homogeneous clear liquid. [85] [86] Table 4 MMPS-PEG derivative nano-dispersion solution water phase
- a water phase containing MMPS-PEG derivative (for example, 94.54 g) was stirred and kept at 50 °C in a receptacle.
- a liquid nano-dispersion solution inversion phase (for example, 5.46 g) was stirred and added to the water phase.
- the MMPS-PEG derivative or the pharmaceutically acceptable salt thereof according to the invention highly inhibits a growth of tumor xenografted to the mammal, thereby treating or preventing a cancer or a cancer-related disease.
- a solubility of the monomethylphytosphingosine is improved and a toxicity thereof influencing on the human body is reduced, thereby remarkably expanding the application ranges thereof. Accordingly, the composition containing the same can be efficiently used as a tumor inhibiting composition, an anti- cancer composition for treating or preventing a cancer or a cancer-related disease or a composition for treating or preventing a hyper-proliferative disease.
Abstract
Disclosed are a monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative formed by combining monomethylphytosphingosine (MMPS), which is a derivative of sphingolipid, with polyethyleneglycol (PEG) or a pharmaceutically acceptable salt thereof and a composition containing the same. The compound inhibits a growth of tumor xenografted to the mammal, thereby treating or preventing a cancer or a cancer-related disease. In addition, it is possible to inhibit an activity of promoting a cell proliferation, thereby treating or preventing a hyper-proliferative disease such as a cancer and psoriasis. Further, a solubility of the monomethylphytosphingosine is improved and a toxicity thereof influencing on the human body is reduced, thereby remarkably expanding the application ranges thereof.
Description
Description
MONOMETHYLPHYTOSPHINGOSINE-POLYETHYLENEGLY COL AND THE COMPOSITION FOR ANTI-CANCER CONTAINING THE SAME Technical Field
[1] The present invention relates to a derivative of sphingolipid having an anti-cancer activity and a composition containing the same, and more particularly to a monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative formed by combining monomethylphytosphingosine (MMPS), which is a derivative of sphingolipid, with polyethyleneglycol (PEG) or a pharmaceutically acceptable salt thereof and a composition containing the same.
[2] Background Art
[3] Sphingolipid was firstly found by Thudichum in 1884 and named as a sphinx like substance. It was known as a substance playing a substantial role in life phenomena as well as regulating cell growth, proliferation and differentiation.
[4] The sphingolipid in a human body has sphingosine, phytosphingosine or sphinganine backbones and 300 or more kinds of derivatives including ceramide having fatty acids connected to the backbones.
[5] The sphingolipid is a main ingredient constituting a cell membrane together with phospholipid and has polar and non-polar parts. Ceramide having a fatty acid connected to sphingolipid is known as a substance playing an important role in causing various action mechanisms occurring in a cell. In particular, it takes part in a cell proliferation, a cell differentiation, a temporary growth arrest of the cell proliferation and an apoptosis.
[6] Since 1990's, functions of the sphingolipid have been analyzed in earnest. In particular, the researches thereof have been actively performed as a protein kinase inhibiting effect of sphingosine was validated by Hannun and Bell, etc. In addition, as it was found that an important life phenomenon such as the cell differentiation, growth, aging and death is regulated by ceramide, it was become a core of a biology research.
[7] The ceramide is a substance causing an apoptosis which is an importance mechanism for a cancer treatment and thus development of an anti-cancer drug is focused on the ceramide. It is analyzed that many anti-cancer drugs, which are being currently used or developed, influence on a biosynthesis pathway of the ceramide and thus exhibit their effects.
[8] As a treatment for killing a cancer cell, ceramide and ceramide derivative and
analog are directly treated to the cancer cell or a substance inducing or starting a de novo synthesis of ceramide may be used as an anti-cancer drug.
[9] Accordingly, since a substance regulating an activity of enzyme participating in biosynthesis of ceramide and sphingolipid is highly possibly to be developed as an anti-cancer drug, it is recently taken intensive interests. Serine palmitoyl transferase (SPT), ceramidase, sphingomyelinase (SMase), gluco-sylceramide (GlcCer) synthase and sphingosine kinase, etc. are enzymes participating in synthesis and hydrolysis of ceramide, and substances for activating and inhibiting such enzymes suggest a possibility of properly regulating a content of ceramide in a cancer cell and thus inducing an apoptosis of the cancer cell.
[10] Researches on substances regulating a content of ceramide in a cell can be confined to developments of derivatives and analogs of sphingolipid and cermide and include many kinds of substances, for example, functional fatty acids, vitamins, androgen and ROS (reactive oxygen species: hydroxyperoxide, nitric oxide releasing compound) influencing on biosynthesis of sphingolipid, and substances influencing on a glutathione (GSH) level and a lecithin level.
[11] Among them, P-drug, which has been actively researched as an anti-cancer drug in recent years, is a ceramide analog of aminoalcohols. PDMP (D-threo-l-phenyl-2-decanoylamino-3-mo holino-l-propanol) among them is an initial synthesis substance which is most developed and exhibits an excellent effect as an inhibitor of a synthesis of GlcCer(glucosyl ceramide) greatly influencing on a cell cycle. PPMP (D-1hreo-l-phenyl-2-palmitoylamino-3-moφholino-l-propanol) having a better effect than PDMP is a homolog having a longer chain and PPPP (P4D-1hreo-l-phenyl-2-palmitoylamino-3-pyrrolidino-l-propanol) is also an analog exhibiting an inhibitory effect higher than PDMP. The P-drug is expected to exhibit an anti-cancer effect for a general cancer cell and to inhibit a synthesis of GlcCer relating to tolerance to the anti-cancer drug, thereby contributing to a prevention of drug resistance.
[12] In addition, B13 or N-oleoylethanolamine, which are ceramidase inhibitors, is also a ceramide analog and inhibits a decomposition of the ceramide to induce a death of the cancer cell. Further, there are ceramide biosynthesis inhibitors having a structure similar to those of sphingolipid and ceramide, such as FTY-720, fumonisin and myriosin, etc.
[13] There are many substances which have been already used as an anti-cancer drug, among the substances participating in the ceramide biosynthesis. Vincristine, gemcitabine, camptothecin, homocamptothecin, irinotecan, etc, are representative examples, most of which promote an activity of SMase. However, since GlcCer and sphingosine 1 -phosphate (SIP) produced from ceramide promote a cancer cell growth,
it is expected that a development of a selective inhibitor of GlcCer synthase, ceramidase or sphingosine kinase (SPHK) will be an efficient treatment strategy for cancer. In particular, the SPHK inhibitor is a development target for a new anti-cancer drug and thus being recently researched.
[14] As a new anti-cancer target, many concerns have been recently focused on dimethylsphingosine (DMS) produced by methylation of sphingosine and safingol which is an isomer of sphinganine, which are known as a SPHK inhibitor. In fact, according to a study of a M.D. Anderson cancer research institute, the DMS was shown to have an efficacy for an acute leucosis exhibiting a drug resistance and a possibility of being developed into an anti-cancer drug was confirmed. In addition, researches on a specific structure capable of regulating contents of sphingolipid and ceramide in a cell by using such substances have been actively progressed.
[15] In addition, various substances have been suggested to increase practical uses of sphingolipid and ceramide. In particular, since ceramide having polyethylene glycol connected thereto renders a liposome be easily formed and increases a circulation lifetime, researches on such substances and a composition for liposome formation are being progressed.
[16] In the mean time, since the sphingolipid has a poor solubility, there are many restraints to apply it to various formulations.
[17] The polyethylene glycol above mentioned is a substance having a structure of HO- (CH CH O) CH CH -OH, and often used in foods or cosmetics. In addition, since it 2 2 n 2 2 retards decomposition of an active ingredient, it has been much used in prescription of drug. The polyethylene glycol is a substance suitable for such purposes since it is a non-toxic polymer, has a good solubility and no antigenicity in a human body and is easily removed in the body. Since the polyethylene glycol has a hydroxyl group at both ends thereof, monomethoxy polyethylene glycol (CH 3 O-(CH 2 CH 2 O) n CH 2 CH 2 -OH) having one end blocked is much used in PEGylation and its molecular weight is used up to 30,000 Daltons. In order to connect monomethoxy polyethylene glycol to a drug, a hydroxyl group at one end having no methoxy connected thereto is activated and connected using various chemicals.
[18] Disclosure of Invention Technical Problem
[19] Accordingly, the inventors applied various changes of a functional group to a basic structure of sphingolipid and thus synthesized derivatives having a new structure, an anti-cancer efficacy and an improved solubility through a medical chemistry molecule design. As a result of that, it was validated that monomethylphytosphingosine-
polyethyleneglycol (MMPS-PEG) exhibits an excellent anti-cancer efficacy, an improved solubility and an effect of reducing a toxicity influencing on the human body.
[20] Accordingly, the present invention has been made to solve the above-mentioned problems occurring in the prior art. The object of the present invention is to inhibit a growth of tumor xenografted to a mammal using a derivative of sphingolipid, i.e., a monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative formed by combining monomethylphytosphingosine (MMPS) with polyethyleneglycol (PEG), thereby treating or preventing a cancer or a cancer-related disease. Another object of the invention is to inhibit an activity of promoting a cell proliferation, thereby treating or preventing a hyper-proliferative disease such as a cancer and psoriasis. Accordingly, the object of the invention is to provide a tumor inhibiting composition, an anti-cancer composition or composition for treating or preventing a hyper-proliferative disease, which compositions have the above-mentioned efficacies.
[21] Technical Solution
[22] In order to accomplish the objects, there is provided a monomethylphy- tosphingosine-polyethyleneglycol (MMPS-PEG) derivative formed by combining monomethylphytosphingosine (MMPS) with polyethyleneglycol (PEG) and having a following chemical formula 1 or a pharmaceutically acceptable salt thereof and a composition containing the same.
[23]
[24] ChemistryFigure 1
[25]
[26] wherein R is independently hydrogen, alkyl group of C , alkenyl group of C , alkynyl group of C , acyl group or aryl group, in a case of acyl group (COR ), R is alkyl group, alkenyl group, alkynyl group or aryl group, a substituent X is a medium used to combine with sphingolipid and -NR -, -O-, -S-, or X -alk-X , R is hydrogen, alkyl group of C 1-6 , acyl group or aryl group, X 1 and X2 are independently amino group, amido group, carboxyl group, carbamate group, carbonyl group, urea or phosphoro, and alk is alkylene of C . [27] In the monomethylphytosphingosine-polyethyleneglycol derivative of the invention,
the polyethyleneglycol has a molecular weight of 550 ~ 10,000, more preferably, 750 ~ 5,000 and an end replaced with methoxy.
[28] A representative example of the monomethylphytosphingosine-polyethyleneglycol derivatives according to the invention is one wherein R is independently hydrogen, alkyl group or acyl group, X is succinate and the polyethyleneglycol has a molecular weight of 750 ~ 5,000 and an end replaced with methoxy group.
[29] According to the invention, there is provided a tumor inhibiting composition containing the monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative or a pharmaceutically acceptable salt thereof as an effective ingredient.
[30] In addition, the tumor inhibiting composition is used to treat or prevent a cancer or cancer-related disease.
[31] According to the invention, there is provided an anti-cancer composition for treating or preventing a cancer containing the monomethylphytosphingosine- polyethyleneglycol (MMPS-PEG) derivative or a pharmaceutically acceptable salt thereof as an effective ingredient.
[32] According to the invention, there is provided a composition for treating or preventing a hyper-proliferative disease containing the monomethylphytosphingosine- polyethyleneglycol (MMPS-PEG) derivative or a pharmaceutically acceptable salt thereof as an effective ingredient.
[33] In addition, the hyper-proliferative disease is psoriasis.
[34] The composition of the invention containing the monomethylphytosphingosine- polyethyleneglycol (MMPS-PEG) derivative or a pharmaceutically acceptable salt thereof can be used in a medicine. The salt is not specifically limited if it is pharmaceutically acceptable. For example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid, acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methane sulfonic acid, benzene sulfonic acid, toluene sulfonic acid and naphthalene sulfonic acid, etc. can be used.
[35] The monomethylphytosphingosine-polyethyleneglycol derivative having the chemical formula 1 according to the invention can be prepared by reacting monomethylphytosphingosine having a following chemical formula 2 with polyethyleneglycol which is activated in advance in a solvent under presence of catalyst.
[36] ChemistryFigure 2
H
[37] Advantageous Effects
[38] The MMPS-PEG derivative or the pharmaceutically acceptable salt thereof according to the invention highly inhibits a growth of tumor xenografted to the mammal, thereby treating or preventing a cancer or a cancer-related disease. In addition, according to the invention, it is possible to inhibit an activity of promoting a cell proliferation, thereby treating or preventing a hyper-proliferative disease such as a cancer and psoriasis. Further, a solubility of the monomethylphytosphingosine is improved and a toxicity thereof influencing on the human body is reduced, thereby remarkably expanding the application ranges thereof. Accordingly, the composition containing the same can be efficiently used as a tumor inhibiting composition, an anti- cancer composition for treating or preventing a cancer or a cancer-related disease or a composition for treating or preventing a hyper-proliferative disease.
[39] Brief Description of the Drawings
[40] FIG. 1 is a graph showing an anti-cancer efficacy of a MMPS-PEG derivative in a nude mouse; and
[41] FIG. 2 is a graph showing a survival rate of a nude mouse having a tumor grafted thereto which is treated with the MMPS-PEG derivative.
[42] Best Mode for Carrying Out the Invention
[43] Hereinafter, the present invention will be more specifically described.
[44] A detailed description of a method of manufacturing the monomethylphy- tosphingosine-polyethyleneglycol derivative having the chemical formula 1 is as follows. Firstly, polyethyleneglycol is activated. Succinic anhydride is added to the polyethyleneglycol under presence of an organic solvent, thereby converting an alcohol group into a carboxyl group. An acid part of the polyethyleneglycol having carboxyl group replaced is activated using triethylamine and p-toluenesulfonylchloride and then a small amount of monomethylphytosphingosine is added to the activated solution a small amount by a small amount, thereby completing a 24 hours reaction under warming conditions.
[45] The compound having the chemical formula 1 prepared as described above is
extracted using an organic solvent such as chloroform or a mixed solution of chloroform and methanol and then purified with an adsorption chromatography by silica gel.
[46] The purified monomethylphytosphingosine-polyethyleneglycol derivative can be used in a medicine as it is or in a form of pharmaceutically acceptable salt. The salt is not specifically limited if it is pharmaceutically acceptable. For example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid, acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methane sulfonic acid, benzene sulfonic acid, toluene sulfonic acid and naphthalene sulfonic acid, etc. can be used.
[47] In the monomethylphytosphingosine-polyethyleneglycol derivative of the invention, the polyethyleneglycol has preferably a molecular weight of 550 ~ 10,000, more preferably 700 ~ 5,000. The range of the molecular weight is the most optimal range for achieving a purpose of combining the polyethyleneglycol.
[48] In addition, a pharmaceutical composition containing the monomethylphy- tosphingosine-polyethyleneglycol derivative or the pharmaceutically acceptable salt thereof preferably contains 0.001 ~ 20 wt.% of the compound in a total composition. When the concentration is less than 0.001 wt.%, it is difficult to obtain the efficacy and when the concentration is more than 20 wt.%, it can cause an abnormality of a generative function.
[49] It can be expected that the monomethylphytosphingosine-polyethyleneglycol derivative of the invention inhibits a growth of tumor grafted in a living mammal and has an increased solubility and a decreased toxicity.
[50] The inventors measured an in vivo anti-cancer activity using a derivative of sphingolipid, i.e., the monomethylphytosphingosine-polyethyleneglycol derivative (MMPS-PEG) having the chemical formula 1 formed by combining monomethylphytosphingosine (MMPS) with polyethyleneglycol (PEG). Specifically, the anti-cancer efficacy of the monomethylphytosphingosine-polyethyleneglycol was measured by xenografting human breast cancer cells, i.e., MDA-MB-231 to a nude mouse. As a result of that, it was validated that the compound exhibited an anti-cancer efficacy almost similar to that of TAXOL which is an existing anti-cancer drug.
[51] In addition, it was also validated a solubility increase and a decrease of toxicity influencing on a human body regarding the compound.
[52] According to the invention, a pharmaceutical composition containing the monomethylphytosphingosine-polyethyleneglycol derivative and the pharmaceutically acceptable salt thereof may further comprise proper carrier, excipient and diluent typically used to prepare the pharmaceutical composition.
[53] The compound of the invention can be pharmaceutically administrated in a form of
a pharmaceutically acceptable salt thereof. Further, it can be administrated solely or in conjunction with and in a proper combination with other pharmaceutically acceptable active compounds.
[54] The pharmaceutical composition containing the compound of the invention can be used in forms of oral formulation such as acida, granulum, tablet, capsule, suspension, emulsion, syrup and aerosol, external preparations such as ointment and cream, suppository and sterilizing injection solution according to typical methods. Further, it can be formulated in any forms suitable for pharmaceutical preparations.
[55] Although a preferable dosage of the compound according to the invention varies with ages, sexes, weights, symptoms and degrees of diseases of administration subjects, drug forms, administration routes and administration periods, it can be properly selected by a skilled person in the art. However, considering a preferable efficacy, it is preferred that the compound of the invention is administrated in an amount of 0.001 ~ 1000 mg/kg per a day. The administration can be performed one time or many times per a day. In addition, the dosage can be increased or decreased according to the ages, sexes, weights, degrees of diseases and administration routes, etc. Accordingly, the dosage does not limit a scope of the invention in any way.
[56] The compound of the invention can be administrated to a mammal such as a rat, a mouse, a domestic animal and a human through various routes, for example, non-oral and oral administrations. All types of the administration can be expected. For instance, it can be administrated with oral, rectum or vein, muscle, hypodermic, and intrauterine dura mater or intracerebroventricular injections.
[57] Since the monomethylphytosphingosine-polyethyleneglycol derivative and the salt containing the same according to the invention have little serious toxicity and side effect, they can be safely used for a prevention purpose for a long time.
[58] Mode for the Invention
[59] Hereinafter, the invention will be more specifically described with reference to examples and experimental examples. However, it should be noted that a scope of the invention is not limited to the examples in any way.
[60]
[61] Example 1: synthesis of monomethylphytosphingosine-polyethylenegl col (MMPS-PEG) derivative
[62] 5.0 g of methoxypolyethyleneglycol (0.0067 mole) was dissolved in pyridine solvent under nitrogen gas and 6.67 g of succinic anhydride (0.067 mole) was slowly added to the solution. After that, the mixture was reacted for 24 hours under state that light was excluded. After the reaction was completed, the pyridine was converted into
a salt form by adjusting to pH 2 with an addition of hydrofluoric acid, and then extracted and removed by adding chloroform and water. At this time, an excess amount of succinic anhydride was extracted and removed as a water layer. 1 g of methoxypolyethyleneglycol-carboxyl acid (0.0011 mole) obtained through the above procedures was dissolved in dichloromethane solvent under nitrogen gas, a carboxyl group thereof was activated using 0.17 ml of triethylamine (0.0017 mole) and 2.11 g of p-toluenesulfonylchloride (0.011 mole), 0.22 g of N-methylphytosphingosine (0.0011 mole) was slowly added, and then a reaction was progressed for 24 hours under warming conditions. After the reaction was completed, the reaction was stopped with distilled water extraction. Then, it was obtained the compound having the chemical formula 1 through an adsorption chromatography by silica gel. In addition, the succinate, which was introduced in the methoxypolyethyleneglycol by reacting with succinic anhydride, was confirmed with H NMR (Avance 500, Bruker) (d = 2.6 ppm, t, 4H). Finally, methylene (d = 1.2 ppm, m, 48H) and (d = 0.9 ppm, t, 6H) of monomethylphytosphingosine, and ethoxy (d = 3.6 ppm, m, 64H) and methoxy (d = 3.3 ppm, s, 3H) of methoxypolyethyleneglycol were confirmed, and it was therefore confirmed that a monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative was synthesized, which is a derivative of the invention formed by combining methoxypolyethyleneglycol with monomethylphytosphingosine.
[63]
[64] Experimental example 1: anti-cancer efficacy of MMPS-PEG derivative in an experimental animal (in vivo efficacy evaluation of MMPS)
[65] In order to validate an anti-cancer efficacy of the MMPS-PEG derivative prepared according to the example 1, a following experiment as a pre-clinical experiment was performed using a nude mouse as an experimental animal. At this time, experimental animals exhibiting a weight increase and an abnormality in a general symptom during the experiment period were excluded from an experiment result.
[66] Firstly, a sufficient amount of human breast cancer cell line, i.e., MDA-MB-231 (obtained from Korea Institute of Radiological and Medical Sciences, Gongneung- dong, Seoul) was cultivated and about 10 of cells were injected into nude mouses (6-week of age, about 20 g, 6 (six) per group, SLC, Japan). After few days, when a size of tumor was increased to about 3 mm, the MMPS-PEG derivative of the Example 1 was injected in the nude mouse (125 mg/kg, three times of intraperitoneal administration) and fractionation-injection conditions of test materials were set while measuring the tumor size. In addition, regarding evaluations of anti-cancer efficacy, the tumor size was measured using calipers per day and a survival rate of the treatment group was evaluated. At this time, phosphate buffered solution (PBS) was used as a negative control group and TAXOL was used as a positive control group in the
experiment.
[67] As a result of that, as can be seen from Fig. 1, MMPS-PEG derivative (125 mg/kg, three times of intraperitoneal administration) exhibited an anti-cancer efficacy almost similar to that of TAXOL (30 mg/kg, three times of intraperitoneal administration) which is an anti-cancer drug currently used in clinic, although there is a difference between concentrations exhibiting the efficacies.
[68] In addition, the survival rates are shown in Fig. 2. As can be seen from Fig. 2, all mouses of the negative control group were dead on 45 days, but 50% of the group injected with the MMPS-PEG derivative was survived.
[69] Formulation examples of the composition are set forth as follows. However, it should be noted that the examples are given only to illustrate the invention, not to limit it.
[70] [71] <Formulation example 1: MMPS-PEG derivative 2% cream> [72] Table 1
[73] [74] Stearyl alcohol, cetyl alcohol, sorbitan monostearate and isopropyl myristate were introduced in a double- walled receptacle and then the mixture was heated until it was completely dissolved. The mixture was added to a mixture of purified water, propylene glycol and polysorbate 60 separately prepared using a liquid homogenizer at 70-75 °C. The produced emulsion was continuously mixed and cooled to below 20 °C. Subsequently, the solution of MMPS-PEG derivative, polysorbate 80 and purified water and the anhydrous sodium sulfite solution in the purified water were added to the emulsion while continuously mixing the solutions. The cream was homogenized and
filled in a proper tube.
[75] <Formulation example 2: MMPS-PEG derivative 2% local gel> [76] Table 2
[77] [78] A proper amount of hydrochloric acid was added to be a solution. A proper amount of sodium hydroxide was added to be pH 6.0. A proper amount of purified water was added to be 100 mg.
[79] MMPS-PEG derivative was added to a solution of hydroxypropyl b-cyclodextrin in purified water while stirring it. Hydrochloric acid was added to be a solution and then sodium hydroxide was added to be pH 6.0. This solution was added to a dispersion solution of carrageenan PJ in propylene glycol while mixing it. The mixture was heated to 50 °C while slowly mixing, and added with ethyl alcohol and then cooled to about 35 °C. A remaining amount of purified water was added to the mixture and then the mixture was mixed to be homogeneous.
[80] [81] <Formulation example 3: MMPS-PEG derivative nano-dispersion solution> [82] Table 3 MMPS-PEG derivative nano-dispersion solution inversion phase
[83] [84] Migliol 812, MMPS-PEG derivative and polysorbate 80 were mixed. Phosphatidyl choline was dissolved in ethanol and then added to the mixture to obtain a homogeneous clear liquid.
[85] [86] Table 4 MMPS-PEG derivative nano-dispersion solution water phase
[87] [88] A water phase containing MMPS-PEG derivative (for example, 94.54 g) was stirred and kept at 50 °C in a receptacle. A liquid nano-dispersion solution inversion phase (for example, 5.46 g) was stirred and added to the water phase.
[89] Industrial Applicability
[90] As described above, the MMPS-PEG derivative or the pharmaceutically acceptable salt thereof according to the invention highly inhibits a growth of tumor xenografted to the mammal, thereby treating or preventing a cancer or a cancer-related disease. In addition, according to the invention, it is possible to inhibit an activity of promoting a cell proliferation, thereby treating or preventing a hyper-proliferative disease such as a cancer and psoriasis. Further, a solubility of the monomethylphytosphingosine is improved and a toxicity thereof influencing on the human body is reduced, thereby remarkably expanding the application ranges thereof. Accordingly, the composition containing the same can be efficiently used as a tumor inhibiting composition, an anti- cancer composition for treating or preventing a cancer or a cancer-related disease or a composition for treating or preventing a hyper-proliferative disease.
Claims
[1] A monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative having a following chemical formula 1 or a pharmaceutically acceptable salt thereof, [Chemistry Figure 1]
[2] A tumor inhibiting composition containing the monomethylphytosphingosine- polyethyleneglycol (MMPS-PEG) derivative or the pharmaceutically acceptable salt thereof according to claim 1 as an effective ingredient.
[3] An anti-cancer composition for treating or preventing a cancer or cancer-related disease containing the monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative or the pharmaceutically acceptable salt thereof according to claim 1 as an effective ingredient.
[4] A composition for treating or preventing a hyper-proliferative disease containing the monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative or the pharmaceutically acceptable salt thereof according to claim 1 as an effective ingredient.
[5] The composition according to claim 4, wherein the hyper-proliferative disease is psoriasis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2004-0039704 | 2004-06-01 | ||
| KR1020040039704A KR100736145B1 (en) | 2004-06-01 | 2004-06-01 | Monomethylphytosphingosine-Polyethyleneglycol and the composition for anti-cancer containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005118522A1 true WO2005118522A1 (en) | 2005-12-15 |
Family
ID=35462863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2005/001438 WO2005118522A1 (en) | 2004-06-01 | 2005-05-17 | Monomethylphytosphingosine- polyethylenegly col and the composition for anti-cancer containing the same |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR100736145B1 (en) |
| WO (1) | WO2005118522A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| KR20030014780A (en) * | 2001-08-13 | 2003-02-20 | 주식회사 참 존 | Phytosphingosine derivatives with antirumor activity |
| WO2003092667A1 (en) * | 2002-05-02 | 2003-11-13 | Doosan Corporation | Composition for treating cancer containing n,n-dimethylphytosphingosine |
| WO2003101937A1 (en) * | 2002-05-31 | 2003-12-11 | Bundle David R | Synthetic methods for the large scale production from glucose of analogs of sphingosine, azidosphingosine, ceramides, lactosyl ceramides, and glycosyl phytosphingosine |
| WO2004054963A1 (en) * | 2002-12-13 | 2004-07-01 | Doosan Corporation | Sphingolipid derivatives modified by polyethylene glycol and composition containing the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60117900D1 (en) | 2001-09-05 | 2006-05-11 | Charmzone Co | Phytosphingosine derivatives with anti-tumor activity |
| KR100459484B1 (en) * | 2002-05-20 | 2004-12-03 | 한국원자력연구소 | Radiosensitizer composition containing N-acetylphytosphingosine and dimethylphytosphingosine as the active ingredients |
| KR20050051862A (en) * | 2003-11-28 | 2005-06-02 | 주식회사 두산 | Sphingolipid-peg derivatives and composition for skin external use containing the derivatives |
-
2004
- 2004-06-01 KR KR1020040039704A patent/KR100736145B1/en not_active IP Right Cessation
-
2005
- 2005-05-17 WO PCT/KR2005/001438 patent/WO2005118522A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| KR20030014780A (en) * | 2001-08-13 | 2003-02-20 | 주식회사 참 존 | Phytosphingosine derivatives with antirumor activity |
| WO2003092667A1 (en) * | 2002-05-02 | 2003-11-13 | Doosan Corporation | Composition for treating cancer containing n,n-dimethylphytosphingosine |
| WO2003101937A1 (en) * | 2002-05-31 | 2003-12-11 | Bundle David R | Synthetic methods for the large scale production from glucose of analogs of sphingosine, azidosphingosine, ceramides, lactosyl ceramides, and glycosyl phytosphingosine |
| WO2004054963A1 (en) * | 2002-12-13 | 2004-07-01 | Doosan Corporation | Sphingolipid derivatives modified by polyethylene glycol and composition containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050114478A (en) | 2005-12-06 |
| KR100736145B1 (en) | 2007-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11306057B2 (en) | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms | |
| US11339125B2 (en) | Use of isothiocyanate functional surfactants as NRF2 inducers to treat epidermolysis bullosa simplex and related diseases | |
| US10343990B2 (en) | Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases | |
| US11648230B2 (en) | Method for treating rheumatoid arthritis | |
| EP2504311B1 (en) | Arachidonic acid analogs and methods for analgesic treatment using same | |
| US11633376B2 (en) | Method for treating metastatic prostate cancer | |
| EP0807115A4 (en) | High molecular weight polymer-based prodrugs | |
| RU2624446C2 (en) | Tricyclic compounds, compositions containing these compounds and their use | |
| US20160317479A1 (en) | Method of treating or preventing pain | |
| US10336777B2 (en) | Cysteine-modifying substrate analogue inhibitors of ribose 5-phosphate isomerase for parasitic diseases, along with methods of their formation and use | |
| EP2475361B1 (en) | N-substituted benzenepropanamides for use in the treatment of pain and inflammation | |
| CA2849055C (en) | N-substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders | |
| WO2005118522A1 (en) | Monomethylphytosphingosine- polyethylenegly col and the composition for anti-cancer containing the same | |
| CA2482784A1 (en) | Composition for treating cancer containing n,n-dimethylphytosphingosine | |
| US20060100289A1 (en) | Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain | |
| KR100705054B1 (en) | Monomethylphytosphingosine and the composition for anti-cancer containing the same | |
| US6593340B1 (en) | Pharmaceutical compositions containing N-propargylphentermine and related analogs to treat neurodegeneration and/or depression | |
| PT86918B (en) | PROCESS FOR THE PREPARATION OF SUBSTITUTED PHENYLUS COMPOUNDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |